Skip to content

Press releases

Discover latest product news and media coverage about Ultromics.

Ultromics granted CPT III reimbursement code for EchoGo® Heart Failure

Ultromics granted CPT III reimbursement code for EchoGo® Heart Failure

Ultromics announces new CPT III code to facilitate clinical reimbursement for EchoGo® Heart Failure.
Ultromics announces partnership to expedite development of Echo AI algorithm for earlier detection of cardiac amyloidosis

Ultromics announces partnership to expedite development of Echo AI algorithm for earlier detection of cardiac amyloidosis

New partnership with Pfizer will expedite the development of an Echo AI algorithm for the early detection of Cardiac Amyloidosis.
CMS publishes final Clinical APC rule for Ultromics EchoGo® Heart Failure

CMS publishes final Clinical APC rule for Ultromics EchoGo® Heart Failure

Ultromics has received New Technology Add-On Payment (NTAP), Advancing HFpEF Diagnosis.
New Technology Add-On Payment (NTAP) for Ultromics: Advancing HFpEF Diagnosis

New Technology Add-On Payment (NTAP) for Ultromics: Advancing HFpEF Diagnosis

Ultromics has received New Technology Add-On Payment (NTAP), Advancing HFpEF Diagnosis.
Study Confirms Ultromics’ AI Can Improve HFpEF Detection Using a Single Echocardiogram View

Study Confirms Ultromics’ AI Can Improve HFpEF Detection Using a Single Echocardiogram View

Ultromics has received FDA clearance for its breakthrough device EchoGo® Heart Failure: A first-of-kind AI-based platform that enables precision detection of HFpEF
CMS Establishes HCPCS code for Ultromics EchoGo® Heart Failure, Accelerating Access to Precision HFpEF Detection

CMS Establishes HCPCS code for Ultromics EchoGo® Heart Failure, Accelerating Access to Precision HFpEF Detection

CMS Establishes HCPCS code for Ultromics EchoGo® Heart Failure, Accelerating Access to Precision HFpEF Detection.
Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection

Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection

Ultromics granted FDA Breakthrough Device Designation for its Amyloidosis device
Ultromics announces new chairman of the board

Ultromics announces new chairman of the board

Ultromics announces the appointment of John Russell as the new Executive Chairman.
Ultromics receives FDA clearance for its breakthrough device for HFpEF detection

Ultromics receives FDA clearance for its breakthrough device for HFpEF detection

Ultromics has received FDA clearance for its breakthrough device EchoGo® Heart Failure: A first-of-kind AI-based platform that enables precision detection of HFpEF
Ultromics increases diagnostic accuracy of stress echocardiography, in six NHS hospitals

Ultromics increases diagnostic accuracy of stress echocardiography, in six NHS hospitals

EchoGo Core, an AI-powered platform from Ultromics, utilizes AI to deliver a fully automated and more precise analysis of an echocardiogram..read more..
AI outperforms human analysis in predicting cardiac outcomes, research initiative by WASE finds.

AI outperforms human analysis in predicting cardiac outcomes, research initiative by WASE finds.

Ultromics’ AI technology analyzes echocardiogram images and predicts cardiac-related mortality better than human analysis.
Ultromics joins FNIH partnership to transform heart failure detection

Ultromics joins FNIH partnership to transform heart failure detection

Ultromics joins FNIH Partnership to Transform Heart Failure Detection. Developing precision treatment strategies for HFpEF is more critical than ever..

Curious about upcoming research and innovation?

Sign-up to hear about the latest news.

 

Sign up to newsletter

mail
534518

cases processed